{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:41:17Z","timestamp":1781376077835,"version":"3.54.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MC"],"published-print":{"date-parts":[[2025,10,8]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Hepatitis B virus (HBV) infection remains a significant public health challenge.\nTargeting HBV capsid assembly has the potential to achieve a functional cure for HBV infection,\nand the capsid assembly modulators (CAMs) have been regarded as promising therapeutic\nagents for HBV. In this work, we aimed to identify novel scaffold HBV CAMs through a multi-step\nvirtual screening approach.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Pharmacophore-based virtual screening combined with hydrogen bond constraints was\nperformed on the Specs and ChemDiv databases. Potential modulators were screened using qPCR\n(quantitative PCR) and CCK-8 assays. Molecular dynamics (MD) simulations and ADMET (absorption,\ndistribution, metabolism, excretion, and toxicity) analysis were employed to evaluate\nligand-protein binding modes and pharmacokinetic properties.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Twenty-one compounds were selected as potential HBV CAMs. Compounds B5, B19, and\nB21 exhibited excellent anti-HBV activity, with EC50 values of 1.74, 4.29, and 0.38 \u03bcM, respectively.\nMD simulations revealed their possible binding modes with the HBV core protein, confirming\nthe critical role of Trp102-mediated hydrogen bonds.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p>Hydrogen bonds are critical for establishing stable and high-affinity interactions between\nsmall molecules and targets. Three compounds, B5, B19, and B21, were identified as novel\nscaffold hits of CAMs through virtual screening with the combination of pharmacophore modeling\nand hydrogen bond constraints. MD simulations illustrated the critical contributions by Trp102,\nproviding valuable insights for further structural optimization.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Compounds B5, B19, and B21 can serve as promising starting points for the development\nof more potent anti-HBV candidates through future hit-to-lead optimization.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115734064409397250925105306","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:26:11Z","timestamp":1760513171000},"source":"Crossref","is-referenced-by-count":1,"title":["Virtual Screening of HBV Capsid Assembly Modulators with the Combination of Pharmacophore Modeling and Hydrogen Bond Constraints"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4978-7954","authenticated-orcid":true,"given":"Hui","family":"Zhao","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwen","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Yan","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-431X","authenticated-orcid":true,"given":"Rong","family":"Sheng","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:26:18Z","timestamp":1760513178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/245896\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115734064409397250925105306","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}